Cardiology Pharmaceuticals June 2, 2025
Deeper Answers from the ABYSS Trial June 2, 2025
Diving deeper into the ABYSS trial, a new sub-analysis suggests that patients with MI and preserved LVEF who stop taking their beta-blockers experience significant rises in heart rate and BP, potentially increasing their risk of adverse events.
Cardiology Business May 29, 2025
Boston Scientific Bows Out on TAVR May 29, 2025
Marking its departure from the TAVR market, Boston Scientific officially discontinued sales of its Acurate neo2 and Acurate Prime TAVR systems and will no longer seek approval from the FDA or other regulatory agencies.
Surgeries & Interventions May 22, 2025
Navitor Versus Sapien 3 Ultra: Different in the Details May 22, 2025
One year data from the NAVULTRA study published in JACC suggests that Edwards’ Sapien 3 Ultra and Abbott’s Navitor intra-annular TAVR valves have similar short-term clinical outcomes, with a few key differences.
Cardiology Pharmaceuticals May 19, 2025
Wegovy Rapidly Lowers MACE Risk May 19, 2025
Getting us closer to understanding GLP-1s’ heart benefits, a post hoc analysis of the SELECT trial suggests that Novo Nordisk’s Wegovy (semaglutide) significantly reduces a patient’s MACE risk in just three months of treatment.
Cardiology Pharmaceuticals May 15, 2025
Tirzepatide Beats Semaglutide in Weight Loss May 15, 2025
Has a king of the GLP-1s finally been crowned? Full results from the SURMOUNT-5 trial published in NEJM seem to suggest that Eli Lilly’s tirzepatide (Zepbound/Mounjarno) could be better than Novo Nordisk’s semaglutide (Wegovy/Ozempic).
Cardiology Testing May 12, 2025
Predicting ASCVD With Calprotectin May 12, 2025
Knowing which biomarkers to look for is critical to diagnosing and preventing ASCVD, and a new JAMA study suggests calprotectin could be the key to catching ASCVD early.
Cardiology Pharmaceuticals May 8, 2025
Obicetrapib Puts on a Show May 8, 2025
Results from NewAmsterdam Pharma’s Phase 3 BROADWAY and TANDEM trials suggest that obicetrapib could be an effective LDL-C lowering treatment, both on its own or combined with another drug.
Cardiology Pharmaceuticals May 8, 2025
Marea Makes Progress on MAR001 May 8, 2025
Marea Therapeutics presented positive data from the Phase 2a clinical trial of its fat-targeting monoclonal antibody, MAR001, that could help address lipid and metabolic drivers of ASCVD.
Surgeries & Interventions May 5, 2025
FDA Approves TAVR for Asymptomatic AS May 5, 2025
TAVR will officially be an option for asymptomatic patients with severe aortic stenosis following the FDA’s approval of Edwards Lifesciences’ SAPIEN 3 platform for the patient group.
Cardiology May 1, 2025
Cardiac Wire’s Top Six of HRS 2025 May 1, 2025
Heart Rhythm Society and sunny San Diego brought together the biggest HRS in years, with everything from custom presentation theaters to exciting after parties.
Atrial Fibrillation April 28, 2025
GLP-1s Add AFib To Their Benefits List April 28, 2025
It seems like every week we’re discovering a new GLP-1 cardiac benefit, with the TRANSFORM-AF study now suggesting the drug could help reduce AFib burden.
Surgeries & Interventions April 24, 2025
RESILIA’s Eight Year Results Impress for SAVR April 24, 2025
Eight-year data presented at HVS 2025 suggests that SAVR valves that use Edwards Lifesciences’ RESILIA tissue have better long-term outcomes compared to non-RESILIA bioprosthetic SAVR valves.
Artificial Intelligence April 21, 2025
How AI is Expanding ECG and Echo’s Applications April 21, 2025
Building stronger evidence for AI’s place in cardiology, this week brought several examples of how AI can improve ECG use cases and automate Echo for new disease detection methods.
Cardiology Pharmaceuticals April 17, 2025
Verve Vaults Forward From Topline Results April 17, 2025
Completing its pharma comeback story, Verve Therapeutics announced successful results from the Heart-2 Phase 1b Clinical Trial of its in-vivo base editing drug, VERVE-102, that targets the PCSK9 gene for reducing LDL-C.
Cardiology Pharmaceuticals April 14, 2025
At Home Nasal Sprays and PSVT ER Visits April 14, 2025
Data analysis from the NODE-301 Phase 3 trial suggests that patients self-adminstering Milestone Pharmaceuticals’ etripamil (CARDAMYST) might be able to avoid ER visits for paroxysmal supraventricular tachycardia (PSVT).
Cardiology Practices April 10, 2025
Does Value Based Care Improve Cardiology? April 10, 2025
Casting doubt on value based cardiac care, a JAMA study found that outpatient cardiology practices enrolled in an accountable care organization (ACO) through the Medicare Shared Savings Program (MSSP) don’t offer better care than non-ACO practices.
Atrial Fibrillation April 7, 2025
PFA or Cryoballoon for Paroxysmal AFib? April 7, 2025
Expanding the potential patient population for pulsed field ablation, results from the SINGLE SHOT CHAMPION study suggest PFA might be just as good as cryoballoon ablation for patients with paroxysmal AFib.
Cardiology April 3, 2025
The Top Trends of ACC.25 April 3, 2025
The ACC 2025 meeting is all wrapped up after matching the attendance and excitement of last year’s expo, with a clear trend toward better diagnostics and even better pharmaceuticals. Among dozens of highlights, here are Cardiac Wire’s seven biggest trends from ACC.25.
Surgeries & Interventions March 31, 2025
Abbott Enters Burgeoning IVL Segment March 31, 2025
Intravascular lithotripsy (IVL) may have once been synonymous with Shockwave Medical, but it’s now rapidly becoming one of the hottest segments in interventional cardiology, spurred on by Abbott’s new IVL Investigational Device Exemption (IDE) from the FDA.